IsoPlexis is excited to have been recently featured in an article on Genome Web! The article, “IsoPlexis Demonstrates Expanded Cell Profiling Capabilities in Immunotherapy Study” by Adam Bonislawski discusses a recent Nature Communications paper where scientists used IsoPlexis’ platform “to explore how multifunctional T cells—defined as T cells expressing multiple cytokines and chemokines—impact the effectiveness of ACT treatment” and next generation applications coming from IsoPlexis.
In addition to breakthrough data on T cell persistence in solid tumor indications, this paper highlights the work being done on IsoPlexis’ platform to make an impact across multiple cell types. IsoPlexis is expanding its applications to work on a variety of immune cell types with the release of two new chip solutions in March 2020 and more to come. All of the steps required for a highly multiplexed proteomic workflow are integrated and completely automated in the IsoLight system for all proteomic needs.
In this Nature Communications publication, Parisi et al. used IsoPlexis’ platform to show that mice treated with their kinetically engineered IL-2 receptor agonist had more polyfunctional T cells in their spleens and tumors than mice treated with conventional IL-2, which correlated with persistence. Then, as part of a phase 1 trial, they looked at the polyfunctionality of T cells and NK cells in the blood of melanoma patients treated with this novel agonist and discovered that polyfunctionality was upregulated in these cells as well. This shows the platform’s ability to effectively analyze NK cells circulating in patient blood, among various other cell types.
Sean Mackay, IsoPlexis’ Co-Founder and CEO said, “This is the first time that has been published. A lot of the developers of cancer immunology drugs are focused on things beyond T cells, like natural killer cells and what the mechanistic impact of those cells are on the tumor response, as well as cells like macrophages and monocytes. While we are using the same core platform, the types of cells we are starting to analyze are becoming much more broad, and this is one of the first peer-reviewed publications to highlight some of that.”
This Nature Communications study provides a comprehensive look at how single-cell proteomics has been used in cancer immunotherapy, highlighting IsoPlexis’ impact in this space. This article also featured upcoming innovations that IsoPlexis is announcing this year—from the release of a new single-cell solution for innate and myeloid cells to a breakthrough, fully automated and highly multiplexed bulk ELISA solution. Later in 2020, IsoPlexis will be releasing single-cell phosphoproteomic chips for researchers interested in profiling intracellular signaling in different immune cell types.
To learn more about our fully automated highly multiplexed bulk ELISA solution, download the product sheet below.